Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease

Expert Opinion on Drug Safety

Volumn 13, Issue 8, 2014, Pages 1055-1069

  Faulkner, Michele A ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amantadine; Anticholinergics; Catechol O methyltransferase; Catechol O methyltransferase inhibitors; Dopamine agonists; Dyskinesia; Levodopa; Monoamine oxidase; Monoamine oxidase inhibitors; Parkinson's disease

Indexed keywords

AMANTADINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; TYRAMINE; ANTIPARKINSON AGENT; DOPAMINE;

BLURRED VISION; CONSTIPATION; DAYTIME SOMNOLENCE; DISEASE COURSE; DRUG INDICATION; DRUG SAFETY; DYSKINESIA; FIBROSIS; FOOD AND DRUG ADMINISTRATION; HALLUCINATION; HUMAN; HYPERSOMNIA; IMPULSE CONTROL DISORDER; INSOMNIA; LIVER TOXICITY; MOTOR CONTROL; MOTOR DYSFUNCTION; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PSYCHOSIS; REVIEW; SKIN CANCER; SYMPTOMATOLOGY; URINE RETENTION; VOMITING; XEROSTOMIA; DRUG APPROVAL; METABOLISM; PATHOPHYSIOLOGY; UNITED STATES;

ANTIPARKINSON AGENTS; DOPAMINE; DOPAMINE AGENTS; DRUG APPROVAL; HUMANS; PARKINSON DISEASE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84904504734     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.931369     Document Type: Review

References (156)

1. Mintzer J, Burns A. Anticholinergic sideeffects of drugs in elderly people. J R Soc Med 2000;93:457-62
2. Parkes JD. Adverse effects of antiparkinsonian drugs. Drugs 1981;21:341-53
3. Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q 2001;72:325-36
4. Carbidopa/Levodopa (Sinemet) package insert. Merck & Co., Inc., West Point, PA; 1999
5. Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignant-like syndrome due to levodopa therapy withdrawal. JAMA 1985;245:2792-5
6. Gibb WRG, Griffith DNW. Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome. Postgrad Med J 1986;62:59-60
7. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13
8. Keck PE Jr, Arnold LM. The serotonin syndrome. Psychiatr Ann 2000;30:333-43
9. Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease. Meta-Analysis of randomized controlled trials. Drug Saf 2010;33:147-61
10. Haasio K. Toxicology and safety of COMT inhibitors. Int Rev Neurobiol 2010;95:163-89
11. Stoessl J. Continuous dopaminergic therapy in Parkinson disease: Time to stride back?. Ann Neurol 2010;68:3-5
12. Kostic V, Przedborski S, Flaster E, et al. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991;41:202-5
13. Schrag A, Ben-Shlomo Y, Brown R, et al. Young-onset Parkinson's disease revisited-clinical features, natural history, and mortality. Mov Disord 1998;13:885-94
14. Manson A, Stirpe P, Schrag A. Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. J Parkinsons Dis 2012;2:189-98
15. Muenter MD, Tyce GM. L-dopa therapy of Parkinson's disease: Plasma L dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971;46:231-9
16. Nutt JF. Levodopa-induced dyskinesia: Review, observations, and speculations. Neurology 1990;40:340-5
17. Obeso JA, Rodriguez-Oroz M, Rodriguez MR, et al. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: Problems with the current model. Ann Neurol 2000;47:S22-34
18. Muenter MD, Sharpless NS, Tyce GM, et al.Patterns of dystonia (I-D-I and D-I-D) in response to l-dopa therapy for Parkinson's disease Mayo Clin Proc
19. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998;55(Suppl 1):1-9
20. Guridi J, Gonzalez-Redondo R, Obeso JA. Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease. Parkinsons Dis 2012;2012:943159
21. Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society evidence-based medicine review update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011;249(Suppl 2):352-4
22. Fahn S. Is levodopa toxic?. Neurology 1996;47:S184-95
23. Fahn S. Levodopa-induced neurotoxicity: Does it represent a problem for the treatment of Parkinson's disease?. CNS Drugs 1997;8:376-93
24. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1
25. Olanow CW, Watkins B. Tolcapone: An efficacy and safety review. Clin Neuropharmacol 2007;30:287-94
26. EMEA public statement on the lifting of the suspension of the marketing authorization for tolcapone (Tasmar). The European Agency for the Evaluation of Medicinal Products, London; 2004. Available from: Http://www.ema. europa.eu/docs/en-GB/document-library/ Public-statement/2009/12/ WC500018369.pdf [Last accessed 20 April 2014]
27. Zagmutt FJ, Tarrants ML. Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline. Int J Neurosci 2012;122:345-53
28. Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease. Drugs 2010;33:147-61
29. Bonuccelli U, Pavese N. Dopamine agonists in the treatment of Parkinson's disease. Expert Rev Neurother 2006;6:81-9
30. Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008(2):CDE006564
31. Frucht SJ, Rogers JD, Greene PE, et al. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908-10
32. Permax (pergolide) and generic equivalents. FDA Public Health Advisory. US Food and Drug Administration, Washington DC; 2007. Available from: Http://www.fda. gov/safety/medwatch/safetyinformation/ safetyalertsforhumanmedicalproducts/ ucm152695.htm [Last accessed 18 April 2014]
33. Factor SA. Intermittent subcutaneous apomorphine therapy in Parkinson's disease. Neurology 2004;62(Suppl 4):12-17
34. Lambert D, Waters CH. Comparative tolerability of the newer generation antiparkinsonian agents. Drugs Aging 2000;16:55-65
35. Tuite P, Riss J. Recent developments in the pharmacological treatment of Parkinson's disease. Expert Opin Investig Drugs 2003;12:1335-52
36. Rinne UK, Bracco F, Chouza C, et al. for the PKDS009 Study Group. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs 1998;55(Suppl 1):23-30
37. Rascol O, Brooks DJ, KIorczyn AD, et al. for the 056 Study Group. A fiveyear study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-91
38. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebocontrolled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-7
39. Jansen PA, Herings RM, Samson MM, et al. Quick titration of pergolide in cotreatment with domperidone is safe and effective. Clin Neuropharmacol 2001;24:177-80
40. Senard JM, Brefel-Courbon C, Rascol O, et al. Orthostatic hypotension in patients with Parkinson's disease. Drugs Aging 2001;18:495-505
41. Kujawa K, Leurgans S, Raman R, et al. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol 2000;57:1461-3
42. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: A retrospective autopsy study. Lancet Neurol 2005;4:605-10
43. Saint-Cyr JA, Taylor AE, Lang AE. Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology 1993;43:S47-52
44. Zhou C-Q, Li S-S, Chen Z-M, et al. Rotigotine transdermal patch in Parkinson's disease: A systematic review and meta-Analysis. PLoS One 2013;8(7):e69738
45. Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: A meta-Analysis. Drug Saf 2003;26:439-4
46. Sprenger FS, Seppi K, Poewe W. Drug safety evaluation of rotigotine. Expert Opin Drug Saf 2012;11:503-12
47. Wright CE, Sisson TL, Ichhpurani AK, et al. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 1997;37:520-5
48. Bonuccelli U, Ceravolo R. The safety of dopamine agonists in the treatment of Parkinson's disease. Expert Opin Drug Saf 2008;7:111-27
49. Kvernmo T, Härter S, Bürger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006;28:1065-78
50. Wang LS, Zhou G, Zhu B, et al. St. John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004;75:191-7
51. Wenk M, Todesco L, Krahenbuh S. Effect of St. John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, Nacetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol 2004;57:495-9
52. Bonuccelli U. Comparing dopamine agonists in Parkinson's disease. Curr Opin Neurol 2003;16(Suppl 1):S13-19
53. Foley P, Gerlach M, Double KL, et al. Dopamine receptor agonists in the therapy of Parkinson's disease. J Neural Transm 2004;111:1375-446
54. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002;41:261-309
55. Tan EK, Ondo W. Clinical characteristics of pramipexole-induced oedema. Arch Neurol 2000;57:729-32
56. Kujawa K, Leurgans S, Raman R, et al. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch Neurol 2000;57:1461-3
57. Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac vulvulopathy in Parkinson disease. A case-control study. Neurology 2006;67:1225-9
58. Zadikoff C, Rochon P, Lang A. Cardiac valvulopathy associated with pergolide use. Can J Neurol Sci 2006;33:27-33
59. Pritchett AM, Morrison JF, Edwards WD, et al. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002;77:1280-6
60. Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: A new complication of the ergotderivative dopamine agonists. Mov Disord 2004;19:56-62
61. Pinero A, Marcos-Alberca P, Fortes J. Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 2005;353:1976-7
62. Van CG, Flamez A, Cosyns B, et al. Heart valvular disease in patients with Parkinson's disease treated with highdose pergolide. Neurology 2003;61:859-61
63. Antonini A, Poewe W. Fibrotic heartvalve reactions to dopamine-Agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826-9
64. Serratrice J, Disdier P, Habib G, et al. Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 2002;10:334-6
65. McElvaney NG, Wilcox PG, Churg A, et al. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease. Arch Intern Med 1988;148:2231-6
66. Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot-And nonergot-derived dopamine agonists. Mov Disord 2009;24:129-33
67. Muller T, Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clin Neuropharmacol 2003;26:109-11
68. Sanjiv CC, Schulzer M, Mak E, et al. Daytime somnolence in patients with Parkinson's disease. Parkinsonism Relat Disord 2001;7:283-6
69. Ferreira JJ, Desboeuf K, Galitzky M, et al. Sleep disruption, daytime somnolence and sleep attacks in Parkinson's disease: A clinical survey in PD patients and age-matched healthy volunteers. Eur J Neurol 2006;13:209-14
70. Homann CN, Wenzel K, Suppan K, et al. Sleep attacks in patients taking dopamine agonists: Review. BMJ 2002;324:1483-7
71. Ebersbach G, Norden J, Tracik F. Sleep attacks in Parkinson's disease: Polysomnographic recordings. Mov Disord 2000;15:187-8
72. Olanow CW, Schapira A, Roth T. Waking up to sleep episodes in Parkinson's disease Mov Disord 2000;15:212-15
73. Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005;62:1377-81
74. Perez-Lloret S, Bondon-Guitton E, Rascol O, et al. Adverse drug reactions to dopamine agonists: A comparative study in the French pharmacovigilance database. Mov Disord 2010;2:1876-80
75. Pirtošek Z. Bad guys' among the antiparkinson drugs. Psychiatr Danub 2009;21:114-18
76. Happe S, Berger K; On behalf of the FAQT Study Investigators. The association of dopamine agonists with daytime sleepiness, sleep problems and quality of life in patients with Parkinson's disease. A prospective study. J Neurol 2001;248:1062-7
77. Furumoto H. Excessive daytime somnolence in Japanese patients with Parkinson's disease. Eur J Neurol 2004;11:535-40
78. Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (non-ergot) dopamine agonists. Arch Neurol 2004;61:97-102
79. Kelley BJ, Duker AP, Chiu P. Dopamine agonists and pathologic behaviors. Parkinsons Dis 2012;2012:603631
80. McCabe C, Harwood J, Brouwer S, et al. Effect of pramipexole on the processing of rewarding and aversive taste stimuli. Psychopharmacology (Berl) 2013;228:283-90
81. Driver-Dunckley E, Samanta J, Stady M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2001;61:422-3
82. Heinonen EH, Myllylä VV. Safety of selegiline (Deprenyl) in the treatment of Parkinson's disease. Drug Saf 1998;19:11-22
83. Youdim MBH, Gross A, Finberg JPM. Rasagiline [N-propargyl-1R(+)- Aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001;132:500-6
84. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-83
85. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561-6
86. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268-78
87. Chen JJ, Wilkinson JR. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: Is tyramine a challenge?. J Clin Pharmacol 2012;52:620-8
88. Finberg JPM. Pharmacology of rasagiline, a new MAO-B inhibitor drug for the treatment of Parkinson's disease with neuroprotective potential. Rambam Maimonides Med J 2010;1(1):e0003
89. Rasagiline (Azilect) package insert. TEVA Neuroscience, Inc; Kansas City, MO; 2006
90. Riederer P, Youdim MBH. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with L-deprenyl. J Neurochem 1986;46:1359-65
91. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parksinon's disease. Neurology 1997;48:1070-7
92. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989;245:519-22
93. Myllylä VV, Sotaniemi KA, Vuorinen JA, et al. Selegiline as initial treatment in denovo parkinsonian patients. Neurology 1992;42:339-43
94. Pålhagen S; Swedish Parkinson Study Group. Selegiline as initial treatment of Parkinson's disease-Swedish multicenter study [abstract]. Mov Disord 1997;12:142
95. Allain H, Courgnard J, Neukirch H-C, et al Selegiline in De novo parkinsonian patients: The French selegiline multicentrer trial (FSMT). Acta Neurol Scand 1991;136:73-8
96. Wiseman LR, McTavish D. Selegiline: A review of its clinical efficacy in Parkinson's disease and its clinical potential in Alzheimer's disease. CNS Drugs 1995;4:230-46
97. Lavie P, Wajsbort J, Youdim MBH. Deprenyl does not cause insomnia in parkinsonian patients. Commun Psychopharmacol 1980;4:303-7
98. Heinonen EH, Rinne UK, Tuominen J. Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-Term levodopa treatment. Acta Neurol Scand 1989;126:113-18
99. Perez-Lloret S, Rascol O. Safety of rasagiline for the treatment of Parkinson's disease. Expert Opin Drug Saf 2011;10:633-43
100. Da Prado M, Zürcher G, Wüthrich I, et al. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm Suppl 1988;26:31-56
101. Cuthbert MF, Greenberg MP, Morley SW. Cough and cold remedies: A potential danger to patients on monoamine oxidase inhibitors. Br Med J 1969;1:404-6
102. Selegiline (Eldepryl) package insert. Somerset Pharmaceuticals, Inc., Morgantown, WV; 2009
103. Goren T, Adar L, Sasson N, et al. Clinical pharmacology tyramine challenge study to determine the selectivity of the monamine oxidase inhibitor type B (MAO-B) inhibitor rasagiline. J Clin Pharmacol 2010;50:1420-8
104. deMarcaida JA, Schwid SR, White WB; Parkinson Study Group TEMPO and PRESTO Tyramine Substudy Investigators and Coordinators. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord 2006;21:1716-21
105. The Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: The TEMPO study. Arch Neurol 2002;59:1937-43
106. The Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-Treated patients with Parkinson disease and motor fluctuations: The PRESTO study. Arch Neurol 2005;62:241-8
107. VanDenBerg CM, Blob LF, Kemper EM, et al. Tyramine pharmacokinetics and reduced bioavailability with food. J Clin Pharmacol 2003;43:604-9
108. Brooks DJ. Safety and tolerability of COMT inhibitors. Neurology 2004;62(Suppl 1):S39-46
109. Ceravolo R, Piccini P, Bailey DL, et al. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 2002;43:201-7
110. Gervas JJ, Muradas V, Bazan E, et al. Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 1983;33:278-82
111. Dingemase J, Jorga K, Zurger G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-62
112. Dingemase J, Jorga K, Zurcher G, et al. Multiple-dose clinical pharmacology of the catechol-O-methyltransferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996;50:47-55
113. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-19
114. The Entacapone and Tolcapone Switch Study Investigators. Entacapone to tolcapone switch: Multicenter doubleblind, randomized, active-controlled trial in advanced Parkinson's disease. Mov Disord 2007;22:14-19
115. Poewe WH, Deuschl G, Gordin A, et al. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: A 6-month randomized placebo-controlled double-blind study in Germany and Austria. Acta Neurol Scand 2002;105:245-55
116. Brooks DJ, Sagar H; and the UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and nonfluctuating patients with Parkinson's disease. A randomized, placebocontrolled, double-blind six-month study. J Neurol Neurosurg Psychiatry 2003;74:1064-72
117. Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998;51:1309-14
118. Larsen JP, Worm-Petersen J, Siden A, et al. The tolerability and efficacy of entacapone over three years in patients with Parkinson's disease. Eur Neurol 2003;10:137-46
119. Mayoral W, Lewis JH, Zimmerman H. Drug-induced liver disease. Curr Opin Gastroenterol 1999;15:208-16
120. Watkins P. COMT inhibitors and liver toxicity. Neurology 2000;55(Suppl 4):S51-2
121. Assal F, Spahr L, Hadengue A, et al. Tolcapone and fulminant hepatitis. Lancet 1998;352:958
122. Bonifati V, Meco G. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease. Pharmacol Ther 1999;81:1-36
123. Colossimo C. The rise and fall of tolcapone. J Neurol 1999;246:880-2
124. Olanow CW. Tasmar Advisory Panel. Tolcapone and hepatotoxic effects. Arch Neurol 2000;57:263-7
125. ICN Polfa Rzeszów S.A. Tolcapone (Tasmar) package insert. Poland. Available from: Http://www.ema.europa. eu/docs/en-GB/document-library/ EPAR-Product-Information/human/ 000132/WC500034731.pdf [Last accessed 28 April 2014]
126. Nissinen E, Kaheinen P, Penttilä KE, et al. Entacapone, a novel catechol-O-methyltransferase inhibitor of Parkinson's disease, does not impair mitochondrial energy production. Eur J Pharmacol 1997;340:287-94
127. Brown GC. Control of respiration and ATP synthesis in mammalian mitochondria and cells. Biochem J 1992;284:1-13
128. Haasio K, Koponen A, Penttilä KE, Nissinen E. Effects of entacapone and tolcapone on mitochondrial membrane potential. Eur J Pharmacol 2002;453:21-6
129. Terada H. Uncouplers of oxidative phosphorylation. Environ Health Perspect 1990;87:213-18
130. Smith KS, Smith PL, Heady TN, et al. In vitro metabolism of tolcapone to reactive intermediates: Relevance to tolacpone liver toxicity. Chem Res Toxicol 2003;16:123-8
131. Fisher A, Croft-Baker J, Davis M, et al. Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov Disord 2002;17:1362-5
132. Beck S, Hubble J, Reinikainen K. Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov Disord 2002;17:1397-9
133. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease. The STRIDE-PD study. Ann Neurol 2010;68:18-27
134. Ongoing safety review of Stalevo and possible increased cardiovascular risk. FDA Drug Safety Communication. US Food and Drug Administration, Washington, DC; 2010. Available from: Http://www.fda. gov/Drugs/DrugSafety/ ucm223060.htm [Last accessed 16 April 2014]
135. Ongoing safety review of stalevo and possible development of prostate cancer. US Food and Drug Administration, Washington, DC; 2010. Available from: Http://www.fda.gov/ Drugs/DrugSafety/ucm223060.htm [Last accessed 17 April 2014]
136. Lang AE, Lees A. Anticholinergic therapies in the treatment of Parkinson's disease. Mov Disord 2002;17(Suppl 4):S7-S12
137. van Herwaarden G, Berger HJ, Horstinh MW. Short-Term memory in Parkinson's disease after withdrawal of long-Term anticholinergic therapy. Clin Neuropharmacol 1993;16:438-43
138. Feinberg M. The problems of anticholinergic adverse effects of in older patients. Drugs Aging 1993;3:335-48
139. Jitapunkal S, Pillay I, Ebrahim S. Delirium in newly admitted elderly persons: A prospective study. Q J Med 1992;83:307-14
140. Hughes RC, Polgar JG, Weightman D, et al. Levodopa in parkinsonism: The effects of withdrawal of anticholinergic drugs. Br Med J 1971;2:487-91
141. Horrocks PM, Vicary DJ, Rees JE, et al. Anticholinergic withdrawal and benzhexol treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry 1973;36:936-41
142. Ehrt U, Broich K, Larsen JP, et al. Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: A cohort study. J Neurol Neurosurg Psychiatry 2010;81:160-5
143. Starkstein SE, Bolduc PL, Mayberg HS, et al. Cognitive impairments and depression in Parkinson's disease: A follow up study. J Neurol Neurosurg Psychiatry 1990;53:597-602
144. Perry EK, Kilford L, Lees AJ, et al. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003;54:235-8
145. Han L, Mc Cusker J, Cole M, et al. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med 2001;161:1099-105
146. Deep P, Dagher A, Sadikot A, et al. Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. Synapse 1999;34:131-318
147. Takahasi T, Yamashita H, Zhang Y-X, et al. Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum. Brain Res Bull 1996;41:363-7
148. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review. J Cereb Blood Flow Metab 2000;20:423-51
149. Amantadine (Symmetrel) package insert. Endo Pharmaceuticals, Inc., Chadds Ford, PA; 2003
150. Dallos V, Heathfield K, Stone P, et al. Use of amantadine in Parkinson's disease. Results of a double-blind trial. Br Med J 1970;4:24-6
151. French DD, Margo CE. Postmarketing surveillance of corneal edema, Fuchs Dystrophy, and amantadine use in the Veterans Health Administration. Cornea 2007;26:1087-9
152. Ferreira JJ, Neutel D, Mestre T, et al. Skin cancer and Parkinson's disease. Mov Disord 2010;25:139-48
153. Olsen JH, Friis S, Frederiksen K. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 2006;17:582-7
154. Inzelberg R, Rabey JM, Djaldetti R, et al. Elevated prevalence of malignant melanoma in Israeli patients with Parkinson's disease. Mov Disord 2006;22:S169
155. Bertoni JM, Arlette JP, Fernandez HH, et al. Parkinson's disease and melanoma: An epidemiologic evaluation. Ann Neurol 2006;60(Suppl 3):S71-2
156. Sober AJ, Wich MM. Levodopa therapy and malignant melanoma. JAMA 1978;240:554-5